Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Kuros Biosciences share: CHF 10,000 investment a year ago now 13.47% down

If CHF 10,000 had been invested in Kuros Biosciences a year ago (closing price then 26.58 CHF), that would equal 376.223 shares at the last closing price of 23.00 CHF, worth CHF 8,653.12 today. That corresponds to a decline of 13.47 percent. Market capitalization most recently stood at CHF 914.34 million; calculation does not take stock splits or dividends into account. » More on finanzen.net
Kuros confirms full-year targets after strong first half

Kuros reports a strong H1 2026: revenue rose 45% to $92.4 million and adjusted EBITDA increased 61% to $12.5 million, with the margin improving to 13.6%. The company posted a first-time net profit of $4.4 million after a loss in the prior year. Kuros reiterates its full-year targets of at least 35% revenue growth and an adjusted EBITDA margin of around 14%, and it confirms its mid-term 2028 target (revenue $300–330 million, adjusted EBITDA margin ≥20%). To support growth, Kuros is advancing product development, market expansion and production capacity in the US and the Netherlands. » More on finanzen.net
Kuros (Kuros Biosciences) stock: 10,000 CHF investment three years ago would have risen 876.08%

Three years ago the Kuros (Kuros Biosciences) stock traded at 2.09 CHF. A 10,000 CHF investment would be worth 97,607.66 CHF today at a closing price of 20.40 CHF, an increase of 876.08%. Market capitalization most recently stood at 786.78 million CHF; stock splits and dividends were not included in the calculation. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Kuros Biosciences has already paid €0.15 in dividends. The last payout was in April 2022.

Financials

In the last quarter, Kuros Biosciences had revenue of €78.73m and net profit of €3.76m

(EUR)	June 2026	YoY
Revenue	78.73m	-
Gross profit	67.08m	-
Net profit	3.76m	-
EBITDA	6.32m	-

Fundamentals

Metric	Value
Market capitalization	€903.51m
Number of shares	39.76m
52-week high/low	€35.18 - €1.44
Dividends	No
Beta	0.76
P/E ratio	114.03
PEG ratio	0.13
P/B ratio	11.31
P/S ratio	5.92

Company profile

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.

Name	Kuros Biosciences
CEO	Christopher T. Fair
Headquarters	Schlieren, zh Switzerland
Website	kurosbio.com
Sector	Health Care
Industry	Biotechnology
IPO	03/06/2021
Employees	178